KarXT a promessa do mais novo tratamento de esquizofrenia: uma revisão integrativa
DOI:
https://doi.org/10.34119/bjhrv7n9-059Keywords:
antipsicóticos, esquizofrenia, eficáciaAbstract
Este artigo apresenta uma revisão integrativa abrangente da literatura sobre a eficácia e segurança dos tratamentos antipsicóticos em pacientes com esquizofrenia. A pesquisa analisa dados de estudos recentes (2015-2023) que investigam diversos antipsicóticos, suas respostas clínicas e perfis de segurança. Os resultados destacam a importância da personalização do tratamento, levando em consideração as características individuais dos pacientes e as particularidades de cada medicamento. Além disso, os achados ressaltam a necessidade de abordagens multidisciplinares e de pesquisa contínua para otimizar os desfechos clínicos e melhorar a qualidade de vida dos pacientes com esquizofrenia.
References
AZIZ, N., KHAN, N., & HAFIZ, M. (2022). Xanomeline and trospium: potential substitute for conventional antipsychotics. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.5732
BERTONI, R. AND LEAL, F. (2023). Revisão do tratamento da esquizofrenia: monoterapia vs associação de antipsicóticos. Revista Debates Em Psiquiatria, 13, 1-20. https://doi.org/10.25118/2763-9037.2023.v13.414
BREIER, A., BRANNAN, S., PAUL, S., & MILLER, A. (2023). Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology, 240(5), 1191-1198. https://doi.org/10.1007/s00213-023-06362-2
BREIER, A., BRANNAN, S., PAUL, S., & MILLER, A. (2023). Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology, 240(5), 1191-1198. https://doi.org/10.1007/s00213-023-06362-2
CAON, L. (2023). Esquizofrenia infantil: um relato de experiência de um caso clínico complexo com abordagem terapêutica. Inova Saúde, 13(3), 48-51. https://doi.org/10.18616/inova.v13i3.8313
CITROME, L. (2015). Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel. International Journal of Clinical Practice, 69(9), 978-997. https://doi.org/10.1111/ijcp.12714
CITROME, L. (2018). Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment, Volume 14, 2563-2577. https://doi.org/10.2147/ndt.s159704
CORRELL, C., ANGELOV, A., MILLER, A., WEIDEN, P., & BRANNAN, S. (2022). Safety and tolerability of karxt (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia, 8(1). https://doi.org/10.1038/s41537-022-00320-1
CORRELL, C., ANGELOV, A., MILLER, A., WEIDEN, P., & BRANNAN, S. (2022). Safety and tolerability of karxt (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia, 8(1). https://doi.org/10.1038/s41537-022-00320-1
CORRELL, C., ANGELOV, A., MILLER, A., WEIDEN, P., & BRANNAN, S. (2022). Safety and tolerability of karxt (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia, 8(1). https://doi.org/10.1038/s41537-022-00320-1
CORRELL, C., MILLER, A., SAWCHAK, S., KAUL, I., PAUL, S., & BRANNAN, S. (2023). Safety and efficacy of karxt (xanomeline trospium) in schizophrenia in the phase 3, randomized, double-blind, placebo-controlled emergent-2 trial. CNS Spectrums, 28(2), 220-220. https://doi.org/10.1017/s1092852923001360
CORRELL, C., MILLER, A., SAWCHAK, S., KAUL, I., PAUL, S., & BRANNAN, S. (2023). Safety and efficacy of karxt (xanomeline trospium) in schizophrenia in the phase 3, randomized, double-blind, placebo-controlled emergent-2 trial. CNS Spectrums, 28(2), 220-220. https://doi.org/10.1017/s1092852923001360
COSTA, M., SOARES, G., LISBOA, L., & RIBEIRO, P. (2023). Esquizofrenia: perspectivas atuais acerca do diagnóstico, tratamento e evolução clínica da doença. Brazilian Journal of Health Review, 6(1), 61-71. https://doi.org/10.34119/bjhrv6n1-007
DAVIDSON, M., SAOUD, J., STANER, C., NOEL, N., WERNER, S., LUTHRINGER, E., … & LUTHRINGER, R. (2022). Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophrenia Bulletin, 48(3), 609-619. https://doi.org/10.1093/schbul/sbac013
DEAN, B. AND SCARR, E. (2020). Muscarinic m1 and m4 receptors: hypothesis driven drug development for schizophrenia. Psychiatry Research, 288, 112989. https://doi.org/10.1016/j.psychres.2020.112989
DEAN, B. AND SCARR, E. (2020). Muscarinic m1 and m4 receptors: hypothesis driven drug development for schizophrenia. Psychiatry Research, 288, 112989. https://doi.org/10.1016/j.psychres.2020.112989
DEAN, B., BAKKER, G., UEDA, H., TOBIN, A., BROWN, A., & KANAAN, R. (2023). A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Frontiers in Cellular Neuroscience, 17. https://doi.org/10.3389/fncel.2023.1124333
DEAN, B., BAKKER, G., UEDA, H., TOBIN, A., BROWN, A., & KANAAN, R. (2023). A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Frontiers in Cellular Neuroscience, 17. https://doi.org/10.3389/fncel.2023.1124333
FERREIRA, D. AND MENEZES, M. (2023). Distúrbios metabólicos associados ao uso de antipsicóticos: uma revisão. Educação Ciência E Saúde, 9(2). https://doi.org/10.20438/ecs.v9i2.465
GHADERI, A., BANAFSHE, H., MIRHOSSEINI, N., MORADI, M., KARIMI, M., MEHRZAD, F., … & ASEMI, Z. (2019). Clinical and metabolic response to vitamin d plus probiotic in schizophrenia patients. BMC Psychiatry, 19(1). https://doi.org/10.1186/s12888-019-2059-x
KANE, J. (2022). A new treatment paradigm. Journal of Clinical Psychopharmacology, 42(5), S1-S13. https://doi.org/10.1097/jcp.0000000000001596
LEITE, L., SANTOS, K., & VELOSO, L. (2021). As ações de enfermagem voltadas a permanência do paciente esquizofrênico vinculado ao centro de atenção psicossocial caps. Research Society and Development, 10(6), e13010615717. https://doi.org/10.33448/rsd-v10i6.15717
MARTINS, V. (2023). Esquizofrenia e neuroinflamação: uma revisão das pesquisas recentes que exploram as conexões entre a esquizofrenia e processos de neuroinflamação, abrindo caminho para novas estratégias terapêuticas.. Brazilian Journal of Implantology and Health Sciences, 5(5), 399-413. https://doi.org/10.36557/2674-8169.2023v5n5p399-413
NEWCOMER, J., NG-MAK, D., RAJAGOPALAN, K., & LOEBEL, A. (2018). Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a us claims database analysis. BMC Health Services Research, 18(1). https://doi.org/10.1186/s12913-018-3020-2
NUNES, P., VOLTOLINI, C., SILVA, E., & BOLETA-CERANTO, D. (2020). Subtipos de esquizofrenia / sub-types of schizophrenia. Brazilian Journal of Health Review, 3(5), 12196-12199. https://doi.org/10.34119/bjhrv3n5-066
OLIVIERI, M. (2023). O desenvolvimento de diabetes mellitus com o uso crônico de antipsicóticos atípicos em pacientes do caps ii, da cidade de maringá-pr. Research Society and Development, 12(10), e14121043283. https://doi.org/10.33448/rsd-v12i10.43283
SAUDER, C., ALLEN, L., BAKER, E., MILLER, A., PAUL, S., & BRANNAN, S. (2022). Effectiveness of karxt (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Translational Psychiatry, 12(1). https://doi.org/10.1038/s41398-022-02254-9
SAUDER, C., ALLEN, L., BAKER, E., MILLER, A., PAUL, S., & BRANNAN, S. (2022). Effectiveness of karxt (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Translational Psychiatry, 12(1). https://doi.org/10.1038/s41398-022-02254-9
SCHMITZ, A., KREUTZ, O., & SUYENAGA, E. (2015). Antipsicóticos atípicos versus efeito obesogênico sob a óptica da química medicinal. Revista Eletrônica De Farmácia, 12(3), 23. https://doi.org/10.5216/ref.v12i3.33714
SILVA, A., BASTOS, C., DOMINGOS, F., PINTO, M., & SANTANA, C. (2020). Formulário de seguimento farmacoterapêutico a cuidadores de pacientes com esquizofrenia refratária. Revista Científica Multidisciplinar Núcleo Do Conhecimento, 93-107. https://doi.org/10.32749/nucleodoconhecimento.com.br/saude/esquizofrenia-refrataria
SOLMI, M., MURRU, A., PACCHIAROTTI, I., UNDURRAGA, J., VERONESE, N., FORNARO, M., … & CARVALHO, A. (2017). Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management, Volume 13, 757-777. https://doi.org/10.2147/tcrm.s117321
SPAGOLLA, K. AND COSTA, M. (2021). A atuação da enfermagem na assistência ao portador de esquizofrenia no ambiente familiar. Research Society and Development, 10(7), e30410716601. https://doi.org/10.33448/rsd-v10i7.16601
VAIDYA, S., GUERIN, A., & LAWRENCE, A. (2022). Clinical effectiveness of muscarinic receptor-targeted interventions in neuropsychiatric disorders: a systematic review. CNS Drugs, 36(11), 1171-1206. https://doi.org/10.1007/s40263-022-00964-8
VASILIU, O. (2024). The new horizon of antipsychotics beyond the classic dopaminergic hypothesis—the case of the xanomeline–trospium combination: a systematic review. Pharmaceuticals, 17(5), 610. https://doi.org/10.3390/ph17050610
VEDANA, K., CIRINEU, C., ZANETTI, A., & MIASSO, A. (2013). <b>agindo em busca de alívio: enfrentamento da esquizofrenia e dos incômodos ocasionados pelo tratamento medicamentoso</b> doi: 10.4025/cienccuidsaude.v12i1.20342. Ciência Cuidado E Saúde, 12(2). https://doi.org/10.4025/cienccuidsaude.v12i2.20342
YE, N. (2024). Current emerging therapeutic targets and clinical investigational agents for schizophrenia: challenges and opportunities. Medicinal Research Reviews. https://doi.org/10.1002/med.22086
